Terms: = Cervical cancer AND PR, PGR, progesterone receptor AND Treatment
230 results:
1. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
2. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
3. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
4. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
5. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
6. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
[TBL] [Abstract] [Full Text] [Related]
7. Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
Joshy G; Khalatbari-Soltani S; Soga K; Butow P; Laidsaar-Powell R; Koczwara B; Rankin NM; Brown S; Weber M; Mazariego C; Grogan P; Stubbs J; Thottunkal S; Canfell K; Blyth FM; Banks E
BMC Cancer; 2023 Sep; 23(1):774. PubMed ID: 37700229
[TBL] [Abstract] [Full Text] [Related]
8. Assessing Geographic Variation in Rates of cervical cancer and Recurrent or Metastatic cervical cancer Among Medicaid Enrollees.
Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
Am J Clin Oncol; 2023 Sep; 46(9):392-398. PubMed ID: 37459055
[TBL] [Abstract] [Full Text] [Related]
9. Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma.
Lian CL; Zhou R; Zhou Y; Zhou P; Wu SG
Drug Des Devel Ther; 2023; 17():551-562. PubMed ID: 36855516
[TBL] [Abstract] [Full Text] [Related]
10. A cross-sectional study of the prevalence, barriers, and facilitators of cervical cancer screening in family planning clinics in Mombasa County, Kenya.
Eastment MC; Wanje G; Richardson BA; Mwaringa E; Patta S; Sherr K; Barnabas RV; Mandaliya K; Jaoko W; McClelland RS
BMC Health Serv Res; 2022 Dec; 22(1):1577. PubMed ID: 36564740
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial.
Hu Y; Han Y; Shen Y; Chen J; Chen Y; Chen Y; Tang J; Xue M; Hong L; Cheng W; Wang D; Liang Z; Wang Y; Zhang Q; Xing H; Zhang Y; Yi C; Yu Z; Chen Y; Cui M; Ma C; Yang H; Li R; Long P; Zhao Y; Qu P; Tao G; Yang L; Wu S; Liu Z; Yang P; Lv W; Xie X; Ma D; Wang H; Li K
BMC Cancer; 2022 Dec; 22(1):1270. PubMed ID: 36471257
[TBL] [Abstract] [Full Text] [Related]
12. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract] [Full Text] [Related]
13. CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.
Zhang J; Dong D; Wei Q; Ren L
BMC Cancer; 2022 Oct; 22(1):1052. PubMed ID: 36207693
[TBL] [Abstract] [Full Text] [Related]
14. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.
Li J; Zhang X; Mu Z; Sun D; Sun Y; Lin Y
Front Immunol; 2022; 13():943916. PubMed ID: 36003403
[TBL] [Abstract] [Full Text] [Related]
15. Post-recurrence survival analysis of patients with pulmonary recurrence from gynaecologic cancers: a multi-institutional analysis of 122 patients.
Ersak B; Akar S; Demirayak G; Tokalioğlu AA; Aytekin O; Çakir C; Yüksel D; Tokgözoğlu N; Karakaş S; Önder AB; Çelik F; Ayhan S; Ünsal M; Boran N; Kiliç F; Cömert GK; Üreyen I; Toptaş T; Korkmaz V; Özdemir İA; Taşçi T; Türkmen O; Moraloğlu Tekin Ö; Engin-Üstün Y; Turan T
J Obstet Gynaecol; 2022 Oct; 42(7):3277-3284. PubMed ID: 36000815
[TBL] [Abstract] [Full Text] [Related]
16. Application and Clinical Value of Machine Learning-Based cervical cancer Diagnosis and Prediction Model in Adjuvant Chemotherapy for cervical cancer: A Single-Center, Controlled, Non-Arbitrary Size Case-Control Study.
Wang Y; Shen L; Jin J; Wang G
Contrast Media Mol Imaging; 2022; 2022():2432291. PubMed ID: 35821886
[TBL] [Abstract] [Full Text] [Related]
17. Factors associated with delay in specialized treatment after diagnosis of cervical cancer in Bahia State, Brazil.
Silva DS; Pinto MC; Figueiredo MAA
Cad Saude Publica; 2022; 38(5):e00022421. PubMed ID: 35703596
[TBL] [Abstract] [Full Text] [Related]
18. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
[TBL] [Abstract] [Full Text] [Related]
19. Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced cervical cancer.
Liu C; Li X; Li A; Zou W; Huang R; Hu X; Yu J; Zhang X; Yue J
J Immunol Res; 2022; 2022():9621466. PubMed ID: 35419462
[TBL] [Abstract] [Full Text] [Related]
20. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.
Bogani G; Chiappa V; Bini M; Ronzulli D; Indini A; Conca E; Raspagliesi F
Tumori; 2023 Apr; 109(2):244-248. PubMed ID: 35311394
[TBL] [Abstract] [Full Text] [Related]
[Next]
